Ibrance vs Kisqali
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
Maintained by TVPills Editorial Team · Site updated November 4, 2026 (not a product-label review)
| Attribute | US Ibrance | US Kisqali |
|---|---|---|
| Generic name | palbociclib Unverified catalogue summary (Generic name) for Ibrance in US; not checked against current local product information. | ribociclib Unverified catalogue summary (Generic name) for Kisqali in US; not checked against current local product information. |
| Drug class | See official local label Unverified catalogue summary (Drug class) for Ibrance in US; not checked against current local product information. | See official local label Unverified catalogue summary (Drug class) for Kisqali in US; not checked against current local product information. |
| Treats | HR-positive advanced or metastatic breast cancer, in specified HER2-negative and HER2-positive combination regimens Unverified catalogue summary (Treats) for Ibrance in US; not checked against current local product information. | HR-positive, HER2-negative breast cancer Unverified catalogue summary (Treats) for Kisqali in US; not checked against current local product information. |
| Category | Oncology Unverified catalogue summary (Category) for Ibrance in US; not checked against current local product information. | Oncology Unverified catalogue summary (Category) for Kisqali in US; not checked against current local product information. |
| Manufacturer | Pfizer Laboratories (US labeler) Unverified catalogue summary (Manufacturer) for Ibrance in US; not checked against current local product information. | Novartis Unverified catalogue summary (Manufacturer) for Kisqali in US; not checked against current local product information. |
| Year approved | — Unverified catalogue summary (Year approved) for Ibrance in US; not checked against current local product information. | — Unverified catalogue summary (Year approved) for Kisqali in US; not checked against current local product information. |
| Catalogue warning level | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Ibrance in US; not checked against current local product information. | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Kisqali in US; not checked against current local product information. |
| Est. TV ad spend | $80M | $80M |
| Side effects and serious risks | — Unverified catalogue summary (Side effects and serious risks) for Ibrance in US; not checked against current local product information. | — Unverified catalogue summary (Side effects and serious risks) for Kisqali in US; not checked against current local product information. |
Sources and editorial standards
Use the current DailyMed labels to verify approved uses, boxed warnings, and side effects for each medication. Label results can differ by product, strength, and formulation.
Page updated November 4, 2026; the linked resources have not necessarily been reviewed on this date.
Frequently asked questions
Is Ibrance or Kisqali better?
This directory does not compare clinical effectiveness or safety. Listing Ibrance and Kisqali together does not establish shared approved indications, equivalence or suitability as substitutes. Consult the correct local labels and your prescriber.
What's the difference between Ibrance and Kisqali?
The table shows catalogue identification and estimated advertising information for Ibrance and Kisqali, not a verified medical comparison. Medical descriptions, mechanisms and safety summaries are withheld.
Which one spends more on TV ads?
Ibrance has the larger estimated TV advertising budget of the two.